FTC effort to stop Amgen's Horizon takeover faces uphill fight
Reuters
23-05-18 10:10
An uphill battle awaits the Federal Trade Commission (FTC) in its attempt to block Amgen's $27.8bn acquisition of Horizon, industry experts have warned. Those in the sector had not been overly worried about the potential for hedging by regulators as there was limited business overlap, but with Amgen described as leveraging its existing drug sales to force insurers and pharmacies to favour Horizon's own medications, the FTC is attempting to put a new theory before a Trump-appointed judge, one analyst warned.